Summer Sale

50% off Premium Yearly

00days
00hrs
00mins
00secs

NYSE:SYK

Stryker Corp. (SYK)

312.20
+6.56 (2.15%)
as of Jun 12, 2026, 8:00:00 pm Market Open.
258 watching
0
Investor Insights
star iconJun 12, 2026, 12:00 am

This summary was created by AI, based on 6 opinions in the last 12 months.

Stryker Corp. (SYK) faces challenges, including the recent cybersecurity incident affecting production and overall weakness in the health sector, but maintains a strong reputation as a leader in medical devices, particularly in orthopedics. Analysts highlight the attractiveness of the stock’s valuation, with expectations of significant earnings growth, forecasting $15 EPS by 2027 at a 20x PE ratio, driven by a 10% topline growth amidst an aging population. With a consistent market share gain from competitors like JNJ and ZBH, Stryker’s focus on robot-assisted surgeries in orthopedics is expected to double in growth over five years. Despite the current struggles in medtech, experts believe holding onto the stock could be beneficial in the long term, given its strong fundamentals and solid track record of acquisitions.

consensus icon
Consensus
Hold
valuation icon
Valuation
Undervalued
review icon
Similar
ZBH
BUY
Allan Tong’s Discover Picks Stryker enjoyed a bounce after beating Q2 revenues and earnings a month ago, but has been rangebound between $180 and $205 since Easter. Typical of the other medical device stocks here, it has yet to return to pre-COVID highs of $226, but trades at a 27.44x PE, far more reasonable than peers including Intuitive Surgical. Read BDX, BSX, ISRG and Stryker Stock: Top 4 Medical Supply Stocks for our full analysis.
BUY
Medical devices have had a tough year, as elective surgeries have been put on hold. Will continue to do well as surgeries come back. Steep learning curve when it comes to these products, so that's a risk. But once doctors learn the mechanics, they're repeat users. Demographic play. At a good level here.
BUY

Medtronic vs. Stryker Both make medical devices, and have been impacted by COVID, because operations have been delayed. But now those ops are coming back. She owns JNJ instead, which includes a medical devices division. Unless there's a sharp uptick in the virus that shuts down hospitals again, demand for medical devices should rise and should even ramp in the near future.

BUY
He just bought a huge chunk this morning. A company that makes medical devices and is the leader in hips, knees and shoulder replacement. The sales force is their moat. It is able to pivot really quickly. They produce the best products, makes good acquisitions and deploys cash well.
TOP PICK
They make medical and surgical equipment in orthopedics. They just bought a hands-and-ankles medical company. Most elective surgeries were postponed in the pandemic, but are slowly coming back now which benefits SYK. Salespeople are very knowledgeable about their products. Doctors remain loyal to SYK's products and won't switch to another company. (Analysts’ price target is $205.79)
TOP PICK
A medical device company. Elective surgeries have been slowed during the pandemic, but will still need to done. Demographics mean this will continue to grow. There is brand loyalty in the space as parts are not easily exchangeable. About 25% of cash flow goes to dividends and the rest towards acquisitions and paying down debt. Yield 1.31% (Analysts’ price target is $205.63)
PAST TOP PICK
(A Top Pick May 21/19, Up 4%) It is a good opportunity to buy the stock right here. Elective surgeries are shut down and have to come back. You may have tougher quarters over the next little while.
DON'T BUY
The analysts are calling for about $8 a share which gives a PE of 20 at current prices. The fair market value is a little below the current stock price. His target is about $210 and is an upper boundary. The bottom would be $132. (Analysts’ price target is $8.00)
PAST TOP PICK
(A Top Pick Jun 04/19, Down 7%) He really likes the equipment side of the healthcare industry. There is a bit of a lag for the kind of procedures they are doing. The demographic is really good and people will continue to need knees and hips and so on. He is looking to add more to this industry. He continues to hold it.
DON'T BUY

Likes it. He hasn't bought it, because he isn't sure which stock to own in this sector. Abbott and Boston Scientific are better choices, he thinks, with more upside potential given product innovation.

PAST TOP PICK
(A Top Pick May 21/19, Down 16%) Medical devices, which is very strong. It's a practical way to keep people out of hospitals. Great story about demographics.
BUY ON WEAKNESS

A great medical equipment company. Over time, they've consolidated and grown. Demographic trends are on his side. But he owns Abbott instead; you can't own everything. Wait for more of a pullback to buy. If the PE falls to the low-$20s, step in.

TOP PICK

A manufacturer of medical and surgical devices. The company has had positive sales growth for over 40 years. They do a great job at identifying areas where they are weak, finding a way to fill that gap and executing the strategy quickly. There is not much exposure they hold in China -- fortuitous right now. Yield 1.03% (Analysts’ price target is $232.92)

TOP PICK
A good acquirer and integrator and have a good position in hip and knee replacement. They're aiming for 1,000 robotic installations worldwide, now at 850. They took a drop in their last purchase but they've bounced back. (Analysts’ price target is $232.92)
COMMENT

Investing in healthcare is hard. He holds BDX which he sees it as the shopping mall of healthcare products. He used to own ZBH but they suffered from recalls. He would probably stick to one of the three since he believes they are the best run companies in healthcare.

Showing 76 to 90 of 170 entries